Tradjenta is owned by Boehringer Ingelheim.
Tradjenta contains Linagliptin.
Tradjenta has a total of 10 drug patents out of which 0 drug patents have expired.
Tradjenta was authorised for market use on 02 May, 2011.
Tradjenta is available in tablet;oral dosage forms.
Tradjenta can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone), method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin, method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin, treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment, method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
The generics of Tradjenta are possible to be released after 05 March, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(4 months from now) | |
US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(4 months from now) | |
US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(2 years from now) | |
US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(4 years from now) | |
US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(4 years from now) | |
US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(6 years from now) | |
US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(6 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(7 years from now) | |
US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Mar 30, 2023 |
Drugs and Companies using LINAGLIPTIN ingredient
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin
Dosage: TABLET;ORAL
45
United States
34
Japan
34
European Union
27
China
24
Korea, Republic of
19
New Zealand
13
EA
12
Taiwan, Province of China
10
Mexico
10
Hong Kong
9
Malaysia
9
Brazil
9
Argentina
9
Canada
9
Australia
8
Spain
8
Peru
8
Poland
7
Germany
7
Norway
7
Chile
7
Denmark
6
Portugal
6
Croatia
6
Ukraine
5
Singapore
5
Uruguay
5
South Africa
5
Cyprus
5
Slovenia
5
ME
5
Ecuador
5
RS
3
Hungary
3
Israel
2
Philippines
2
Austria
2
India
2
Luxembourg
1
Turkey
1
Colombia
1
Egypt
1
Morocco
1
Belgium
1
Tunisia
1
Yugoslavia
1
Saudi Arabia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic